ADIA, GIC lead $300m round for China's Taibang Biologic
Taibang Biologic Group, a specialist in blood plasma-based pharmaceuticals formerly known as China Biologic Products, has raised a USD 300m round led by Abu Dhabi Investment Authority (ADIA) and GIC.
It is the company's first funding since being delisted in the US at a USD 4.6bn valuation last year by a Centurium Capital-led consortium. Additional commitments came from the private equity arm of China...
More on Greater China
Latest News
ADIA commits $83m to India's Aditya Birla Health Insurance
Abu Dhabi Investment Authority (ADIA) has agreed to invest INR 6.6bn (USD 83.5m) in India’s Aditya Birla Health Insurance (ADBHI) for a 10% stake.
Bain targets $102m Japan advertising take-private
Bain Capital has won board approval from Net Marketing, a Tokyo-listed online advertising and media management business, for a take-private that values the company at approximately JPY 13.6bn (USD 102m).
China's Insilico Medicine gets another $35m
Insilico Medicine, a China-based artificial intelligence-driven drug discovery company, has closed the second tranche of its Series D round on USD 35m, with Prosperity7 Ventures taking the lead.
Singapore crypto risk platform extends Series A to $24m
Singapore’s Merkle Science, a predictive crypto analytics platform, has raised USD 24m in Series A funding led by K3 Ventures, Darrow Holdings, and Beco Capital.